Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CVS GROUP PLC. We currently have 35 research reports from 1 professional analysts.
|06Feb17 17:25||RNS||Exercise of Options & Total Voting Rights|
|27Jan17 11:27||RNS||Exercise of Options, Director/PCA Dealing & TVR|
|09Jan17 09:01||RNS||Exercise of Options and Total Voting Rights|
|19Dec16 16:48||RNS||Holding(s) in Company|
|19Dec16 12:27||RNS||Holding(s) in Company|
|19Dec16 12:15||RNS||Block Admission|
|14Dec16 13:01||RNS||Result of Successful £30.2 million Placing & TVR|
Frequency of research reports
Research reports on
CVS GROUP PLC
CVS GROUP PLC
N+1 Singer - CVS Group - Fundraising to support ongoing growth
14 Dec 16
CVS has successfully raised £30.2m in an over-subscribed placing with new and existing investors at 1000p. This will help ease pressure on the balance sheet and provide the group with greater firepower to invest for further growth. We estimate re-leveraging the BS back up towards 2x in the next 30 months would augment FY18 EPS by 14%/20% in FY18/FY19. Ultimately, CVS has the platform to be a >£1bn capitalised company in the mid-term and we remain positive. We see ST fair value at 1170p.
N+1 Singer - CVS Group - Proposed placing
13 Dec 16
CVS has announced an intention to conduct a placing to raise at least £30m via an accelerated bookbuild. We feel this is a sensible move to support the strong growth momentum without significantly increasing gearing levels. We put our forecasts under review and will publish updated numbers once the final outcome of the placing is confirmed.
N+1 Singer - Morning Song 13-12-2016
13 Dec 16
ALLIANCE PHARMA (APH LN) Positive CMD provided a detailed insight | CARPETRIGHT (CPR LN) Stock at 20 year low but transformation plan well on track | CVS GROUP PLC (CVSG LN) Proposed placing | MICROSAIC SYSTEMS PLC (MSYS LN) Trading update | NCC GROUP (NCC LN) Confirmation of weak H1’17 | UBM PLC (UBM LN) Acquisition – zig when the others zag | ZYTRONIC (ZYT LN) Strong underlying profit growth; Forecast upgrades
N+1 Singer - CVS Group - Strong AGM prompts double-digit upgrades
24 Nov 16
CVS has issued a strong AGM statement which further justifies its premium rating. For the first 4 months to October it has traded “ahead of the Board’s expectations”, registering an impressive 6.3% LFL showing. It has also been busy consolidating and established a foothold in the Dutch market. We push through 10% EPS upgrades for each of the next 3 years and see further upside risk. The strength of the update shows CVS continues to have strong momentum and we argue for fair value towards 1100p.
N+1 Singer - Morning Song 24-11-2016
24 Nov 16
Abzena (ABZA LN) Positive Phase I/II data on Abzena inside programme OPN-305 | Actual Experience (ACT LN) 3-yr framework agreement with Accenture | CVS Group (CVSG LN) Strong AGM prompts double-digit upgrades | Euromoney Institutional Investor (ERM LN) No change to outlook | Futura Medical (FUM LN) Forecast update post equity capital raise | Marston’s (MARS LN) Solid finals and reassuring tenor | Sigma Capital Group (SGM LN) Milestone reached: 1000th PRS home completed and let | UDG Healthcare (UDG LN) In line prelims, outlook intact
N+1 Singer - CVS Group - Dutch game changer
26 Sep 16
Last week’s finals showed CVS has good momentum with numerous growth levers. Significantly, a potential new addition to the mix is advanced plans to gain a foothold in Holland, as signalled at the analyst meeting. We view this as a game changer. The Dutch veterinary market shares many characteristics to those of the UK and is hugely fragmented. It offers real scope for consolidation, crucially at lower and thus more value accretive multiples than the UK. Capturing a similar market share to the UK currently implies a minimum c.£40m revenue opportunity for CVS. We remain positive on CVS, arguing for ST fair value at 1100p on expectation of over delivery.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
The Crown Joules
15 Feb 17
We believe that own-brand retailers that operate a balanced multi-channel proposition will be well placed to prosper in a competitive apparel market going forward. Joules is one company in particular which we believe will outperform the sector given its loyal and growing customer base, distinctive brand and strong track record of opening profitable space. We initiate coverage on the shares with a buy recommendation and price target of 249p, implying upside of 16.9% over the prevailing market price.
N+1 Singer - Carpetright - Recovery has just begun
17 Feb 17
With UK LFLs up 6.8% in Jan against tough comparatives, and Europe LFLs up 5.4% in Q3, the first clear evidence is now visible that the transformation strategy is gaining momentum. Given some uncertainties, market forecasts are yet to reflect this, but upgrades seem likely as further initiatives are rolled out. Despite a recent bounce from its all time low, the valuation is still very low on consensus assumptions, where risk now appears to be shifting to the upside. With scope for re-rating too, our 300p target price has the scope to grow to 500p over 18 months. We re-initiate with a Buy.
Panmure Morning Note 19-01-2017
19 Jan 17
Pets at Home have released a Q3 trading update this morning that will disappoint the market. Group like-for-like revenue growth was just +0.1% through 3Q16 as subdued trading across the Merchandise business weighed on continued strong growth in Veterinary Services. Profit outlook for FY17 remains in line with expectations. Suspect the shares will come under pressure.